http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H02193925-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14b02369b953bf4ebd31190c8cb63473
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
filingDate 1989-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb57065da4e3cbc8c91f4306cc854d6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23654ecac58a5f19a7854705869c8ad1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e47fe39185defd738dd656a237ebfb68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46df2c4559a0afccac702073ef01d3cc
publicationDate 1990-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H02193925-A
titleOfInvention Vaginal sappository
abstract PURPOSE: To provide a vaginal sappository improved in the absorbability of dehydroepiandrosterone sulfate(DHAS) salt and having excellent storage stability containing the DHAS, an amino acid and a hard fat. n CONSTITUTION: A hard fat having a hydroxyl group value of ≤50 is employed as a base agent, thermally method, homogeneously mixed with the salt of DHAS and an amino acid, poured in a mold by a constant amount and subsequently cooled to provide the objective agent. The hard fat is a mixture of glycerides whose constituting fatty acids are 8-18C straight chain saturated fatty acids The DHAS, the amino acid and the hard fat are compounded in a ratio of 1 pt.wt., 0.2-3 pts.wt. and 1-20 pts.wt., respectively. The vaginal sappository is administered in a pregnant woman of the pregnancy of 37-39 weeks 1-3 times a day at a dosage of 100-1500mg a time as the salt of DHAS. n COPYRIGHT: (C)1990,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012097027-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9745122-A1
priorityDate 1989-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S63104924-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5788113-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5767513-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S56118013-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5881
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID161641
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12594
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415858172
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412583
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553117

Total number of triples: 34.